Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 8 post-ruxolitinib window

Advanced Sleep Architecture Analysis

69 nights analyzed | 2026-01-08 to 2026-03-23 | Ruxolitinib start: 2026-03-16

Generated 2026-03-27 07:09 · Post-HSCT Patient

Fragmentation

Normal

1.5trans/hr

0.0% above clinical threshold

Sleep Efficiency

Low

78.8%

98.6% of nights below 85%

Sleep Cycles

Normal

5.2/night

17.6% below 4 cycles

REM Latency

Normal

75.5min

8.8% above 120 min

HRV Coupling

Abnormal

Abnormal autonomic regulation

Ultradian Period

Normal

97.0min

Expected ~90 min (68 nights)

Clinical Interpretation

ABNORMAL: HRV is NOT higher during deep sleep than during light sleep. Normal parasympathetic dominance during deep sleep is absent - suggests autonomic dysfunction.

Sleep Architecture Analysis (9 panels)

All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.

Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.

Data: January 08 – March 23, 2026 · Post-intervention: 8 days (ruxolitinib, March 16)